The United States Food and Drug Administration (FDA) twice rejected a compound known as flibanserin , a pill that, like the popular viagra for men, increases sexual desire in women. Now, a new panel of advisers has recommended that the US agency approve its commercialization.
In the first occasions that this drug was presented – and rejected – it was due to the fact that the experts considered that there were doubts about its safety and that, in addition , sufficient evidence had not been provided to show that the drug was effective for women with appetite problems sexual.
Now, thanks to this new approval, the United States would be the first to commercialize this female viagra developed by the Sprout Pharmaceuticals laboratory, whose scientists have contributed new studies on flibanserin, which testify to the positive situation of the pill with a view to its sale here to 2016. There are no contraindications for driving , one of the safety details that generated the greatest concern for the panel of experts.
“The flibanserin review represents a critical milestone for the millions of American women and couples living with distress without approved medical treatment to date,” explains Cindy Whitehead, president of Sprout.
The side effects of the “female viagra” that would be marketed under the name “Addyi” are: drowsiness, the possibility of fainting and a decrease in blood pressure. The key to this drug is that it modifies three key chemicals in the brain by increasing dopamine (the happiness hormone) and norepinephrine (the reward system) and decreasing serotonin (the pleasure hormone).
